证券代码：600422 证券简称：昆药集团 公告编号：2024-050 号 昆药集团股份有限公司 关于联合控股股东华润三九召开 2024 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2024 年 8 月 23 日（星期五）至 8 月 29 日(星期四)16:00 前访问全景投资 者关系互动平台（ http://ir.p5w.net/zj/ ）进入问题征集专题页面 ， 或 通 过 公 司 邮 箱 (irm.kpc@kpc.com.cn)向公司提问，公司将在说明会上对投资者普遍关注的问题进行回答。 昆药集团股份有限公司（以下简称"公司"）已于2024年8月23日发布公司2024年半年度报 告，为便于广大投资者更全面深入地了解公司2024年半年度经营成果、财务状况，公司计划 于2024年9月2日下午15:00-16:00，联合公司控股股东华润三九医药股份有限公司（以下简称 "华润三九"）举行2024年半年度网上业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次业 ...

证券代码：600422 证券简称：昆药集团 公告编号：2024-046号 昆药集团股份有限公司十届三十次董事会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 昆药集团股份有限公司（以下简称"昆药集团"、"公司"）于 2024 年 8 月 21 日以 现场+线上会议方式召开公司十届三十次董事会会议。会议通知以书面方式于 2024 年 8 月 11 日发出。会议由公司董事长邱华伟先生召集并主持，本次会议应参加表决董事 9 人，实际参加表决 9 人，符合《公司法》和《公司章程》的规定。会议以记名方式 投票表决，审议并通过以下决议： 1、 关于公司 2024 年半年度报告及摘要的议案（公司 2024 年半年度报告及摘要刊登 于上海证券交易所网站 www.sse.com.cn） 本议案已经公司十届董事会审计与风险控制委员会 2024 年第五次会议审议通过， 并同意提交公司董事会审议。 同意：9 票 反对：0 票 弃权：0 票 同意：9 票 反对：0 票 弃权：0 票 5、 关于落实董事会职权实施方案的议案 2、 关于公司 20 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 担保情况概述 （1）担保事项履行的相关程序 为支持昆药集团股份有限公司（以下简称"公司"）旗下全资及控股子公司 2024 年 生产经营及业务发展需要，满足相关下属公司融资担保需求，经公司十届二十三次董 事会及 2024 年第三次临时股东大会审议通过，2024 年度由公司及下属子公司为旗下 公司合计不超过人民币 6.06 亿元的银行融资授信业务提供连带责任担保，详见《昆药 集团股份有限公司关于 2024 年度担保计划的公告》（2024-015 号）和《昆药集团股 份有限公司 2024 年第三次临时股东大会决议公告》（2024-028 号）。 （2）担保概况 为支持旗下全资及控股子公司生产经营及业务发展，2024 年 8 月 15 日，在上述 批准范围内公司发生如下担保（单位：万元）： | 担保 | 被担 | 担保 | 被担保 | 本次担 | 协议签 | | 本次 | 截止目 | 2024 | 可用担 | 担保额 | 是 | 是 | | --- | --- | ...

Investment Rating - The report indicates a positive outlook for Kunming Pharmaceutical Group, positioning it as a leader in the silver-haired health industry and emphasizing its potential for growth in international markets and innovative drug development [2][34]. Core Insights - Kunming Pharmaceutical Group, with over 600 years of heritage, is recognized for its strong brand in traditional Chinese medicine and has made significant strides in innovation and internationalization [2][34]. - The company has a diverse product matrix, including traditional Chinese medicine, chemical drugs, and innovative pharmaceuticals, with a total revenue of 75.4 billion RMB in 2023 [3][34]. - The strategic focus has shifted towards becoming a leader in the elderly health sector, leveraging its core products, particularly those derived from the traditional herb Sanqi [16][34]. Summary by Sections Business Segments - The company’s revenue is divided into two main segments: pharmaceutical distribution (33.21 billion RMB, 44% of total revenue) and pharmaceutical manufacturing (42.2 billion RMB, 56% of total revenue) [3][4]. - Within pharmaceutical manufacturing, oral medications generated 30.54 billion RMB and injections 10.58 billion RMB, with gross margins of 68.09% and 83.39% respectively [3][4]. Product Categories - The product categories include: - **Plant-based Medicines**: Focused on three key herbs: Sanqi, Tianma, and Qinghao, with significant products like Xuesaitong for cardiovascular diseases and Artemisinin for malaria [5][6]. - **Traditional Chinese Medicine**: Includes a range of products for various clinical areas, such as Shenling Baizhu San and Shugan Wan [7]. - **Chemical Drugs**: Contributing approximately 6 billion RMB in revenue, accounting for about 13% of pharmaceutical manufacturing [8]. Internationalization Efforts - The company has successfully internationalized its products, particularly Artemisinin, which has gained recognition in Africa and has been pre-certified by the World Health Organization [6][34]. - In 2023, Kunming Pharmaceutical submitted 61 registration applications overseas, receiving 30 approvals, marking a significant step in its international expansion [6][34]. Financial Performance - In 2023, the company reported a revenue of 7.54 billion RMB, with a slight decrease of 2.33% year-on-year, while the gross margin improved to 45.41% [3][21]. - The net profit margin increased to 5.8% in 2023, up from 4.6% in 2022, indicating improved profitability [23][34]. Strategic Changes Post-Acquisition - Following the acquisition by China Resources Sanjiu, the company has undergone significant restructuring, focusing on enhancing its market position and operational efficiency [16][35]. - The new strategic vision emphasizes the integration of traditional and modern medicine, aiming to establish a comprehensive health management system targeting the elderly population [16][35].

Summary of the Conference Call Company and Industry Involved - The conference call pertains to Dongwu Pharmaceutical, specifically focusing on the Chinese medicine sector and the performance of Kunming Pharmaceutical [1] Core Points and Arguments - The analyst, Li Qian, emphasizes the anticipation surrounding Kunming Pharmaceutical's performance following its integration into China Resources [1] Other Important but Possibly Overlooked Content - The call is part of a series of in-depth reports on Dongwu Pharmaceutical, indicating a structured approach to analyzing the company's developments and market position [1]

Summary of Conference Call Transcript Company Overview - The company has over 50 subsidiaries involved in various sectors [1] Key Points - In 2022, the company was publicly acquired by China Resources (华润) for a 28% stake [1]

证券代码：600422 证券简称：昆药集团 公告编号：2024-043 昆药集团股份有限公司 2023 年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 三、 相关日期 A 股每股现金红利 0.20 元（含税） 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2024/7/30 | － | 2024/7/31 | 2024/7/31 | 差异化分红送转： 否 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司 2024 年 6 月 21 日的 2023 年年度股东大会审议通过。 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分 公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3. 分配方案： 本次利润分配以方案实施前的公司总股本 757,113,997 股为基数，每股派发现金红 ...

Group 1: Market Development and Product Strategy - The aging population in China is leading to a significant increase in chronic disease management needs, creating a large potential market for the Xuesaitong product series [1] - The company aims to focus on the Sanchi industry chain and provide integrated solutions for chronic disease management and elderly health [1] - The company plans to leverage the strengths of its Xuesaitong series and Huaren Shenghuo's products to create a differentiated market positioning and enhance brand value [1] Group 2: Sales and Market Share - In 2023, the injectable Xuesaitong (freeze-dried) won bids in Shanghai's traditional Chinese medicine procurement, and the Xuesaitong tablets won bids in Shanghai and Zhejiang [2] - The company aims to increase market share and brand awareness through active participation in national and provincial drug procurement [2] - The company plans to enhance its channel coverage and efficiency by expanding grassroots and clinic channels [2] Group 3: Brand Building and Consumer Engagement - The "777" brand will focus on chronic disease and elderly-related diseases, promoting the recognition of effective components in Xuesaitong soft capsules [3] - The company intends to build a comprehensive product line under the "777" brand, covering health management, disease prevention, and rehabilitation [3] - The company will enhance consumer communication to strengthen brand recognition and promote the effectiveness of its products [3] Group 4: Business Growth and Management - The company is restructuring its marketing organization into three core divisions: KPC1951, Kun Traditional Medicine 1381, and 777, to focus on high-performance marketing teams [4] - The integration of sales channels and optimization of the existing business model are ongoing to ensure effective sales and distribution [4] - The company aims to improve its net profit margin through cost reduction and efficiency enhancement strategies post-acquisition by Huaren Sanjiu [4] Group 5: Future Plans and Incentives - The company is in the process of establishing a long-term incentive mechanism to enhance sustainable development and align with strategic goals [5] - Future incentive plans will be disclosed in accordance with relevant laws and regulations as they are developed [5]

Summary of the Conference Call Record Company Overview - The document discusses KunYao Group, which became a subsidiary of China Resources Group in 2023 [1] Key Points and Arguments - In 2023, China Resources Group became the controlling shareholder of KunYao Group, indicating a significant shift in ownership and potential strategic direction for the company [1] Other Important Content - The analysis is structured around both short-term and long-term perspectives regarding the company's future and performance [1]

Summary of the Conference Call Record Company Overview - The document discusses KunYao Group, which became a subsidiary of China Resources Group in 2023 [1] Key Points and Arguments - In 2023, China Resources Group became the controlling shareholder of KunYao Group, indicating a significant shift in ownership and potential strategic direction for the company [1] Other Important Content - The analysis is structured around both short-term and long-term perspectives regarding the company's future and performance [1]